Course of Itch from Systemic Sclerosis Onset: a Scleroderma Patient-Centred Intervention Network Cohort Longitudinal Study

This longitudinal study of over 2,000 systemic sclerosis patients reveals that itch is a common and moderately severe symptom that remains stable in both prevalence and intensity regardless of disease onset age or duration, challenging the previous belief that itch is most significant only in early disease.

The Gist

The Big Question: Does the "Itch" of Scleroderma Fade Away?

Imagine you have a very stubborn, annoying mosquito bite that won't go away. For years, doctors and patients with Systemic Sclerosis (SSc), also known as scleroderma, have believed a specific story about this "mosquito bite" (which is actually a symptom called itch or pruritus).

The Old Story: Everyone assumed that the itch was like a storm that hits hard right when the disease starts (the "early days"), and then slowly, slowly fades away as the years go by. The thinking was: "Once the disease settles down, the itch should go away too."

The New Discovery: This study is like sending a drone up to take a long-term video of that storm. Instead of watching it fade, the drone found that the storm is actually just as strong 20 years later as it was on day one.

The Study: A Long-Term "Weather Report"

The researchers didn't just ask a few people once; they tracked 2,173 people with scleroderma from 7 different countries over many years. They checked in on them every three months, asking, "How bad is your itch right now?" on a scale of 0 (no itch) to 10 (unbearable).

Think of this like a massive, global weather station collecting data on a specific type of rain. They wanted to see if the rain stopped as the "season" (the disease duration) changed or if the "age" of the person changed.

The Results: The "Steady Hum"

The findings were surprising and very consistent. Here is what they found:

1. The Frequency (How many people itch):
   Imagine a room full of 100 people with scleroderma. The study found that 35 to 37 people in that room are itching at any given time.

   • The Analogy: It's like a steady hum in the background. It doesn't matter if the disease has been there for 2 years or 20 years. The "hum" of itching is always there for about one-third of the people. It doesn't get louder or quieter as time passes.

2. The Intensity (How bad it feels):
   For the people who are itching, the pain level is consistently a 4.1 to 4.4 out of 10.

   • The Analogy: On a scale where 0 is "silence" and 10 is "a rock concert next door," the itch is like a loud radio playing in the next room. It's not a whisper, but it's not a scream either. It's a "moderate" annoyance that stays exactly the same whether you've had the disease for a few years or a few decades.

3. The "Age" Factor:
   The researchers checked if older people or people who got the disease at a younger age felt different.

   • The Analogy: It's like checking if a car engine makes a different noise depending on how many miles are on the odometer. They found that the engine noise (the itch) is the same regardless of whether the car is new or has 200,000 miles on it.

Why This Matters: Changing the Map

The Old Map: Doctors used to think, "If you've had scleroderma for a long time, you probably don't need to worry about the itch anymore." They treated the itch as a "new patient" problem.

The New Map: This study draws a new map. It shows that the itch is a permanent resident for many patients, not a temporary visitor.

• The Problem: Because doctors thought the itch would go away, they often didn't ask about it during routine check-ups. They were looking for the storm to pass, so they didn't bring an umbrella.
• The Solution: The study says, "Stop waiting for the storm to pass. Bring the umbrella now." Doctors need to start asking about itch and treating it as a standard part of the disease, just like they do for joint pain or skin tightness.

The Takeaway

Think of the itch in scleroderma not as a firework (bright and loud at the start, then gone), but as a tattoo (it's there from the beginning and stays with you, at the same intensity, for the long haul).

This study tells us that for many people with scleroderma, the itch is a constant, moderate companion. It doesn't get better with time, and it doesn't get worse with time; it just is. The goal now is to stop ignoring it and start finding ways to make that "loud radio" in the next room turn down the volume.

Technical Summary

1. Problem Statement

Systemic sclerosis (SSc), or scleroderma, is a complex autoimmune disease affecting the skin and internal organs. Itch (pruritus) is a common manifestation that significantly impairs quality of life.

• Current Knowledge Gap: While itch is thought to be most severe in the early stages of SSc (when disease activity is highest), this assumption lacks empirical support. Previous research consisted primarily of cross-sectional studies which failed to find a statistically significant association between disease duration and itch. Furthermore, no longitudinal studies had previously mapped the trajectory of itch from disease onset, nor had any study successfully disentangled the effects of chronological aging from the effects of disease duration.
• Objective: To estimate the longitudinal trajectory of past-week itch presence and severity from the onset of SSc, accounting for both participant age and time since symptom onset.

2. Methodology

Study Design and Population

• Design: A longitudinal cohort study utilizing data from the multinational Scleroderma Patient-centred Intervention Network (SPIN) Cohort.
• Participants: 2,173 individuals with confirmed SSc (meeting 2013 ACR/EULAR criteria) recruited from 49 sites across 7 countries (USA, Canada, France, UK, Australia, Mexico, Spain).
• Data Collection: Participants completed assessments at enrolment and every 3 months thereafter. The study analyzed data from April 2014 to October 2020.
• Sample Size: The study included 19,733 itch assessments (mean 9.1 assessments per participant).
• Demographics: 87.3% female; mean age at enrolment 54.7 years; 40.2% had diffuse cutaneous SSc.

Measures

• Primary Outcome: Past-week itch severity measured via a single-item Numerical Rating Scale (NRS) ranging from 0 ("not severe at all") to 10 ("unbearable").
• Predictors:
  • Age at assessment: Partitioned into two distinct variables to avoid collinearity:
    1. Age at onset of non-Raynaud phenomenon (non-RP) symptoms.
    2. Time since non-RP symptom onset.
• Covariates: Country, sex, and SSc subtype (diffuse vs. limited/sine).

Statistical Analysis

• Modeling Approach: The researchers employed two-stage mixed-effects models to address the high proportion of zero scores (participants with no itch):
  1. Stage 1 (Presence): A generalized linear mixed-effects model (GLMM) with a logistic link to estimate the probability of having any itch (score > 0).
  2. Stage 2 (Severity): A linear mixed-effects model to estimate the severity score conditional on the presence of itch.
• Non-linearity Handling: To account for potential non-linear trajectories, basis splines (B-splines) were incorporated using the R splines package. Knots were placed based on quantiles of age and time since onset, with model complexity selected via the Akaike Information Criterion (AIC).
• Random Effects: Random intercepts were included for participants to account for correlations between repeated measures within individuals.
• Sensitivity Analysis: A restricted analysis was performed including only participants who completed their first itch assessment within 10 years of symptom onset to mitigate potential attrition bias (healthier individuals staying in the study longer).

3. Key Contributions

• First Longitudinal Analysis: This is the first study to longitudinally track itch trajectories in SSc from disease onset, moving beyond cross-sectional snapshots.
• Methodological Rigor: The study utilized a sophisticated two-stage modeling approach to simultaneously analyze the probability of itch and the severity of itch, addressing the zero-inflated nature of the data.
• Disentangling Variables: By separating "age at onset" from "time since onset," the study successfully isolated the effects of chronological aging from disease progression, a distinction previous studies could not make.
• Scale: With over 19,000 assessments from >2,000 participants, this is the largest study of itch in SSc to date (over 20 times larger than the next largest study).
• Patient Involvement: The study was co-designed and interpreted with a Patient Advisory Team comprising people with lived experience of SSc.

4. Results

Prevalence (Probability of Itch)

• The predicted probability of experiencing any itch (NRS > 0) was stable across all combinations of age at onset and disease duration.
• Range: Between 35.0% and 36.8% (95% CI: 31.8%–40.4%).
• There was no evidence that itch prevalence decreased in later disease stages or increased significantly with age, contrary to the assumption that itch is primarily an early-disease phenomenon.

Severity (Intensity of Itch)

• Among participants reporting itch, the mean severity was moderate and remained stable over time.
• Range: Between 4.1 and 4.4 on the 0–10 scale.
• Trajectory: For all onset ages, predicted severity decreased by less than 0.2 points for every 10-year increment in disease duration.
• Statistical Interactions: While a statistically significant interaction between age of onset and time since onset was detected for itch presence, the magnitude was negligible (clinically irrelevant). No significant interaction was found for severity.

Subgroup Analysis

• Sex: No significant association between sex and itch presence or severity.
• Country: Participants from countries other than the USA had slightly higher odds of itch presence (OR 1.34–1.78). UK participants had minimally higher severity (~0.1 points difference), which was below the minimally important difference (MID) of 3–4 points.
• Subtype: Diffuse cutaneous SSc was associated with higher odds of itch presence (OR 1.25) compared to limited/sine scleroderma.

5. Significance and Implications

Clinical Implications

• Redefining the Clinical Course: The study refutes the common clinical assumption that itch is a transient symptom limited to early SSc. Instead, itch is a persistent, stable feature affecting roughly one-third of patients throughout the entire disease course.
• Routine Care: Given the stable, moderate-to-severe nature of the symptom, the authors argue that itch assessment and management should be integrated into routine SSc clinical care, rather than being overlooked or assumed to resolve over time.

Research Implications

• Pathophysiology: The stability of itch suggests that the underlying mechanisms (potentially involving cutaneous fibrosis, microvascular injury, and neuro-immune dysregulation) are chronic rather than acute.
• Treatment Development: The findings highlight an urgent need to develop and test specific management strategies for SSc-related pruritus, as current treatments are likely insufficient or underutilized.
• Future Studies: Research should focus on individual-level trajectory patterns to understand why some patients experience itch while others do not, and to identify specific biological markers associated with chronic pruritus in SSc.

Conclusion
This study provides robust evidence that itch in systemic sclerosis is a common (35–37%), moderate (4.1–4.4/10), and stable symptom that does not diminish with disease duration or age. It calls for a paradigm shift in clinical practice to prioritize the evaluation and treatment of itch as a core component of SSc management.